A Randomized, 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO(Rm) (15mg BID [twice daily]) in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Cilomilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- 08 Apr 2008 Status changed from in progress to completed accordnig to ClinicalTrials.gov.
- 03 Oct 2005 New trial record.